Speaker

Martin Hey-Mogensen

Director, Novo Nordisk A/S

Martin Hey-Mogensen, Director, Novo Nordisk A/S, is speaking at 2nd Obesity & Weight Loss Drug Development Summit Europe (Munich, Germany, 28–29 Oct 2026) in the session “Exploring Energy Expenditure as an Alternative Method of Obesity Treatment”.

Conferences: 1
Keynotes: 0
Upcoming: 1

Upcoming appearances

2nd Obesity & Weight Loss Drug Development Summit Europe
28–29 Oct 2026Munich, Germany
- SpeakerExploring Energy Expenditure as an Alternative Method of Obesity Treatment
- PanelPanel & Audience Discussion: Evaluating Oral, Injectable & DNA Delivery Methods to Align Modality Selection with Clinical Performance & Commercial ScaleWith Jacob Jeppesen, Ohad Yogev, Paul Little

More speakers at 2nd Obesity & Weight Loss Drug Development Summit Europe

Anna Altieri
Translational Research Associate, Resalis Therapeutics
Henrik Bjork Hansen
Director - Scientific, Gubra
Steffen-Sebastian Bolz
Executive Board Member and Chief Scientific Officer, APHAIA Pharma AG
Martin Brenner
Chief Executive & Scientific Officer, iBio
Daniel de la Torre
VP of Research & Development, Constructive Bio
Mélanie Flaender
Head of Project Management, Cytoo

See all 16 speakers on the event page

This profile is built from conference programmes published on kongre.net. It has not been claimed or confirmed by Martin Hey-Mogensen, and it lists only the talks, sessions and presentations named in those programmes.

Is this you? Claim this profile — every request is read by a person before anything is linked.

To ask for a correction or for this profile to be removed, email [email protected].